Skip to content
Research Article Open access CC BY 4.0

Global Therapeutic Intervention on Malaria

Augusta Nkiruka Onugha, Chukwunonyerem Chika Ogwunga, Mercy Ngozi Madubuike, Okechukwu Charles Josephat

International Journal of Pathogen Research · pp. 29–38 · Published 10 Aug 2022

10.9734/ijpr/2022/v10i330252

Abstract

Malaria is a vector-borne infectious disease caused by distinct species of a single-celled parasite called Plasmodium sp. However, an infected adult female Anopheles sp. mosquito that feeds on blood is responsible for the transmission of malaria.  In the year 2020, approximately 241 million malaria cases and 627 thousand malaria deaths were recorded globally. In most tropical and subtropical regions of the world, malaria is one of the leading causes of death. Its transmission cuts across 86 countries with African continent recording approximately 95% deaths in 2020. Africa is mostly affected due to its weather conditions that support the easy spread of Plasmodium falciparum. Over time, relevant interventions have been made by researchers in the diagnosis, prevention, and treatment of malaria. Nevertheless, there are still challenges to its treatment and management globally. This review article is focused on the therapeutic intervention on malaria globally. Thus, published primary literatures reporting several relevant and new therapeutic interventions in malaria, as globally attained in the past years were collated and vital information critically reviewed. It is important to note that, the risk of contracting malaria is dependent on the region visited, length of stay, immunity, exposure and compliance with prophylaxis. Hence, to select treatment best suitable as a first-line therapy, combination antimalarial therapy, which consists of two or more antimalarial agents with different mechanisms of action was introduced and has been widely accepted and endorsed to prevent the development of drug resistance. Yet, immunization still remains the best measure for the eradication of malaria.

Malaria immunization malaria prophylaxis Plasmodium falciparium parasite

References (43)

  1. 1 Philosophical Transactions of the Royal Society of London (A) [DOI]
  2. 2 The American Journal of Tropical Medicine and Hygiene [DOI]
  3. 3 Malaria: Biology and Disease [DOI]
  4. 4 Chloroquine‐Resistant Malaria [DOI]
  5. 5 Malaria [DOI]
  6. 6 Artemisinin-Based Combination Treatment of Falciparum Malaria [DOI]
  7. 7 Impact of Artemisinin-Based Combination Therapy and Insecticide-Treated Nets on Malaria Burden in Zanzibar [DOI]
  8. 8 TROPICAL MEDICINE AND INTERNATIONAL HEALTH [DOI]
  9. 9 Malaria biology and disease pathogenesis: insights for new treatments [DOI]
  10. 10 Molecular and biochemical parasitology [DOI]
  11. 11 Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection [DOI]
  12. 12 Severe Malarial Anemia: Innate Immunity and Pathogenesis [DOI]
  13. 13 Strategies for the prevention of antimalarial drug resistance: Rationale for combination chemotherapy for malaria [DOI]
  14. 14 Malaria gametocytogenesis [DOI]
  15. 15 The pathophysiology of falciparum malaria [DOI]
  16. 16 Pitfalls in a Discovery: The Chronicle of Chloroquine [DOI]
  17. 17 A Trial of Combination Antimalarial Therapies in Children from Papua New Guinea [DOI]
  18. 18 Investigating the Pathogenesis of Severe Malaria: A Multidisciplinary and Cross-Geographical Approach [DOI]
  19. 19 Malaria misdiagnosis in Uganda – implications for policy change [DOI]
  20. 20 Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa [DOI]
  21. 21 The consequences of reducing transmission of Plasmodium falciparum in Africa [DOI]
  22. 22 The evolution of drug–resistant malaria: the role of drug elimination half–life [DOI]
  23. 23 Antimalarial drug resistance [DOI]
  24. 24 Host–parasite interactions that guide red blood cell invasion by malaria parasites [DOI]
  25. 25 Long-acting injectable atovaquone nanomedicines for malaria prophylaxis [DOI]
  26. 26 How antimalarial drug resistance affects post-treatment prophylaxis [DOI]
  27. 27 Responding to the Challenge of Antimalarial Drug Resistance by Routine Monitoring to Update National Malaria Treatment Policies [DOI]
  28. 28 A randomized open study to assess the efficacy and tolerability of dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia [DOI]
  29. 29 Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study [DOI]
  30. 30 Comparison of artesunate–mefloquine and artemether–lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial [DOI]
  31. 31 Pre-Erythrocytic Vaccines against Malaria [DOI]
  32. 32 EFFECTIVE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA WITH AZITHROMYCIN-QUININE COMBINATIONS: A RANDOMIZED, DOSE-RANGING STUDY [DOI]
  33. 33 pfmdr1 GENOTYPING AND IN VIVO MEFLOQUINE RESISTANCE ON THE THAI-MYANMAR BORDER [DOI]
  34. 34 Activity of Azithromycin as a Blood Schizonticide against Rodent and Human Plasmodia In Vivo [DOI]
  35. 35 Epigenetic Roulette in Blood Stream Plasmodium: Gambling on Sex [DOI]
  36. 36 Emerging drugs for malaria [DOI]
  37. 37 Intravenous artesunate plus Artemisnin based Combination Therapy (ACT) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial [DOI]
  38. 38 Antimalarial Agents - Chemistry and Pharmacology [DOI]
  39. 39 Declining mefloquine sensitivity of Plasmodium falciparum along the Thai-Myanmar border.
  40. 40 Malaria in the treatment of malaria.
  41. 41 Comparative Clinical Trial of Artesunate and the Combination of Artesunate-Mefloquine in Multidrug-Resistant Falciparum Malaria [DOI]
  42. 42 International Journal on Biological Sciences [DOI]
  43. 43 Mediterranean Journal of Hematology and Infectious Diseases [DOI]

Cited by 5

Covid-19 and Malaria Co-Infection in Imo State, Nigeria: A Descriptive Seroprevalence Study

Chukwunonyerem C. Ogwudire, Mercy N. Madubuike, Christiana E. Etoruom · Asian Journal of Research in Infectious Diseases · 2023

Co-infection of Covid-19 and Malaria among staff and students of Federal University of Technology Owerri, Imo State.

Chukwunonyerem Chika Ogwudire, Mercy Ngozi Madubuike, Christiana Ekele Etoruom · 2023

Structural exploration of the PfBLM Helicase-ATP Binding Domain and implications in the quest for antimalarial therapies

Hattan S Gattan, Bassam M Al-ahmadi, Abdullah F Shater · Journal of Vector Borne Diseases · 2024

Showing 3 of 5 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

34

Page views

0

PDF downloads

3

Outbound clicks

5

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.